Concomitant expression of inhibitory molecules for T cell activation predicts poor survival in patients with esophageal squamous cell carcinoma.

CONCLUSION: Therefore, our results suggest the necessity of evaluating the tumor tissue expression of co-inhibitory molecules and targeting co-expressed molecules in immunotherapies for ESCC patients.
PMID: 33222673 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - November 20, 2020 Category: Cancer & Oncology Authors: Chen Z, Cao K, Zhang J, Liu Z, Lu L, Qi B, Shi L, Huang R, Zhao S Tags: Curr Cancer Drug Targets Source Type: research